Tocqueville Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Tocqueville Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,925	Closed	-$383K	–	1034
2015 Q1	$383K	Hold	3,925	–	–	﹤0.01%	767
2014 Q4	$364K	Sell	3,925 -1,200	-23%	-$94.7K	﹤0.01%	771
2014 Q3	$352K	Sell	5,125 -3,425	-40%	-$245K	﹤0.01%	696
2014 Q2	$896K	Buy	8,550 +1,850	+28%	+$157K	0.01%	602
2014 Q1	$556K	Buy	6,700 +2,600	+63%	+$240K	0.01%	549
2013 Q4	$265K	Hold	4,100	–	–	﹤0.01%	741
2013 Q3	$260K	Buy	+4,100	New	+$202K	﹤0.01%	818

Tocqueville Asset Management's GEVA Position: Q2 2015 in Review

Tocqueville Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 3,925 shares — an estimated $383K sold.

Tocqueville Asset Management first reported a position in GEVA in Q3 2013 and held it in 7 quarters. The position peaked at $896K in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Tocqueville Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Tocqueville Asset Management sold 3,925 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $383K.
Tocqueville Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 7 quarters.
Tocqueville Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $896K in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Tocqueville Asset Management's 13F filing for Q2 2015, filed 31 Jul 2015.